email article Single-agent immune checkpoint inhibition after surgery reduced the risk of disease recurrence or death in patients with high-risk clear cell renal cell carcinoma (RCC), findings from a phase III study showed. The KEYNOTE-564 trial met its primary endpoint, demonstrating that adjuvant pembrolizumab (Keytruda) following nephrectomy significantly increased disease-free survival (DFS) versus placebo (HR 0.68, 95% CI 0.53-0.87, P=0.001), reported Toni Choueiri, MD, of the Dana-Farber Cancer Institute in Boston. At 1 and 2 years, respectively, DFS rates were 85.7% and 77.3% with the PD-1 inhibitor, as compared with 76.2% and 68.1% with placebo, a "clinically meaningful improvement," Choueiri said at a press briefing ahead of the virtual American Society of Clinical Oncology (ASCO) annual meeting.